These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 25843798)
1. Major urinary protein 1 interacts with cannabinoid receptor type 1 in fatty acid-induced hepatic insulin resistance in a mouse hepatocyte model. Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT Biochem Biophys Res Commun; 2015 May; 460(4):1063-8. PubMed ID: 25843798 [TBL] [Abstract][Full Text] [Related]
2. Cannabinoid receptor type 1 mediates high-fat diet-induced insulin resistance by increasing forkhead box O1 activity in a mouse model of obesity. Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT Int J Mol Med; 2016 Mar; 37(3):743-54. PubMed ID: 26847930 [TBL] [Abstract][Full Text] [Related]
3. Endocannabinoid system activation contributes to glucose metabolism disorders of hepatocytes and promotes hepatitis C virus replication. Sun LJ; Yu JW; Wan L; Zhang XY; Shi YG; Chen MY Int J Infect Dis; 2014 Jun; 23():75-81. PubMed ID: 24704332 [TBL] [Abstract][Full Text] [Related]
4. Curcumin ameliorates mitochondrial dysfunction associated with inhibition of gluconeogenesis in free fatty acid-mediated hepatic lipoapoptosis. Kuo JJ; Chang HH; Tsai TH; Lee TY Int J Mol Med; 2012 Sep; 30(3):643-9. PubMed ID: 22692588 [TBL] [Abstract][Full Text] [Related]
5. Cannabinoid-1 Receptor Antagonism Improves Glycemic Control and Increases Energy Expenditure Through Sirtuin-1/Mechanistic Target of Rapamycin Complex 2 and 5'Adenosine Monophosphate-Activated Protein Kinase Signaling. Liu J; Godlewski G; Jourdan T; Liu Z; Cinar R; Xiong K; Kunos G Hepatology; 2019 Apr; 69(4):1535-1548. PubMed ID: 30506571 [TBL] [Abstract][Full Text] [Related]
6. Cannabinoid receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding protein H (CREBH) in primary hepatocytes. Chanda D; Kim DK; Li T; Kim YH; Koo SH; Lee CH; Chiang JY; Choi HS J Biol Chem; 2011 Aug; 286(32):27971-9. PubMed ID: 21693703 [TBL] [Abstract][Full Text] [Related]
8. Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Cinar R; Godlewski G; Liu J; Tam J; Jourdan T; Mukhopadhyay B; Harvey-White J; Kunos G Hepatology; 2014 Jan; 59(1):143-53. PubMed ID: 23832510 [TBL] [Abstract][Full Text] [Related]
9. Cannabinoid type 1 receptor blockade induces transdifferentiation towards a brown fat phenotype in white adipocytes. Perwitz N; Wenzel J; Wagner I; Büning J; Drenckhan M; Zarse K; Ristow M; Lilienthal W; Lehnert H; Klein J Diabetes Obes Metab; 2010 Feb; 12(2):158-66. PubMed ID: 19895638 [TBL] [Abstract][Full Text] [Related]
10. Effects of the cannabinoid CB1 antagonist rimonabant on hepatic mitochondrial function in rats fed a high-fat diet. Flamment M; Gueguen N; Wetterwald C; Simard G; Malthièry Y; Ducluzeau PH Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1162-70. PubMed ID: 19724020 [TBL] [Abstract][Full Text] [Related]
11. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects. Wang X; Liu R; Zhang W; Zhang X; Liao N; Wang Z; Li W; Qin X; Hai C Mol Cell Endocrinol; 2013 Aug; 376(1-2):70-80. PubMed ID: 23791844 [TBL] [Abstract][Full Text] [Related]
12. Novel effects of the cannabinoid inverse agonist AM 251 on parameters related to metabolic syndrome in obese Zucker rats. Merroun I; Sánchez-González C; Martínez R; López-Chaves C; Porres JM; Aranda P; Llopis J; Galisteo M; Zarzuelo A; Errami M; López-Jurado M Metabolism; 2013 Nov; 62(11):1641-50. PubMed ID: 23932644 [TBL] [Abstract][Full Text] [Related]
13. Antidiabetic effects of sub-chronic administration of the cannabinoid receptor (CB1) antagonist, AM251, in obese diabetic (ob/ob) mice. Irwin N; Hunter K; Frizzell N; Flatt PR Eur J Pharmacol; 2008 Feb; 581(1-2):226-33. PubMed ID: 18191122 [TBL] [Abstract][Full Text] [Related]
14. Using proteomics to discover novel biomarkers for fatty liver development and response to CB1R antagonist treatment in an obese mouse model. Chen CC; Lee TY; Kwok CF; Hsu YP; Shih KC; Lin YJ; Ho LT Proteomics; 2017 Jan; 17(1-2):. PubMed ID: 27928909 [TBL] [Abstract][Full Text] [Related]
15. Activation of cannabinoid receptor type 1 (Cb1r) disrupts hepatic insulin receptor signaling via cyclic AMP-response element-binding protein H (Crebh)-mediated induction of Lipin1 gene. Chanda D; Kim YH; Kim DK; Lee MW; Lee SY; Park TS; Koo SH; Lee CH; Choi HS J Biol Chem; 2012 Nov; 287(45):38041-9. PubMed ID: 22989885 [TBL] [Abstract][Full Text] [Related]
16. Coordinated improvement in glucose tolerance, liver steatosis and obesity-associated inflammation by cannabinoid 1 receptor antagonism in fat Aussie mice. Bell-Anderson KS; Aouad L; Williams H; Sanz FR; Phuyal J; Larter CZ; Farrell GC; Caterson ID Int J Obes (Lond); 2011 Dec; 35(12):1539-48. PubMed ID: 21386801 [TBL] [Abstract][Full Text] [Related]
18. Blockade of cannabinoid receptor 1 improves insulin resistance, lipid metabolism, and diabetic nephropathy in db/db mice. Nam DH; Lee MH; Kim JE; Song HK; Kang YS; Lee JE; Kim HW; Cha JJ; Hyun YY; Kim SH; Han SY; Han KH; Han JY; Cha DR Endocrinology; 2012 Mar; 153(3):1387-96. PubMed ID: 22234468 [TBL] [Abstract][Full Text] [Related]
19. Acute cannabinoid receptor type 1 (CB1R) modulation influences insulin sensitivity by an effect outside the central nervous system in mice. Song D; Bandsma RH; Xiao C; Xi L; Shao W; Jin T; Lewis GF Diabetologia; 2011 May; 54(5):1181-9. PubMed ID: 21340622 [TBL] [Abstract][Full Text] [Related]
20. Piperine reverses high fat diet-induced hepatic steatosis and insulin resistance in mice. Choi S; Choi Y; Choi Y; Kim S; Jang J; Park T Food Chem; 2013 Dec; 141(4):3627-35. PubMed ID: 23993530 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]